Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1957 2
1960 1
1962 1
1963 2
1964 1
1966 2
1968 3
1969 1
1970 2
1975 4
1976 1
1977 2
1978 1
1979 3
1980 5
1981 3
1982 4
1983 5
1984 7
1985 1
1986 2
1987 5
1988 10
1989 6
1990 7
1991 8
1992 10
1993 14
1994 15
1995 16
1996 14
1997 31
1998 22
1999 22
2000 20
2001 25
2002 17
2003 24
2004 23
2005 33
2006 38
2007 42
2008 47
2009 41
2010 53
2011 52
2012 47
2013 46
2014 51
2015 62
2016 51
2017 44
2018 31
2019 40
2020 57
2021 67
2022 64
2023 50
2024 51
2025 56
2026 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,256 results

Results by year

Filters applied: . Clear all
Page 1
A randomized controlled trial evaluating the effects of anamorelin in postoperative patients with upper gastrointestinal cancer: protocol for the CLEAR-UP study.
Yamashita K, Nishio K, Mizutani S, Nishimura Y, Tarui M, Sakamoto S, Iwasaki K, Hida E, Nakai S, Hagi T, Momose K, Saito T, Tanaka K, Makino T, Takahashi T, Kurokawa Y, Nakajima K, Eguchi H, Doki Y. Yamashita K, et al. Among authors: nishio k. Jpn J Clin Oncol. 2026 Jan 16:hyaf223. doi: 10.1093/jjco/hyaf223. Online ahead of print. Jpn J Clin Oncol. 2026. PMID: 41543044
Long-term progression-free survivors ("super responders") to olaparib maintenance in recurrent ovarian cancer: a multicenter real-world study (KCOG-G2101s).
Fukuda N, Takashima T, Nakai H, Yoshioka E, Ito K, Taniguchi R, Tsubamoto H, Motohashi T, Fujiwara S, Katsuda T, Nishio S, Nagano H, Nishikawa R, Kai K, Arakawa A, Sakai K, Morii E, Nishio K, Matsumura N. Fukuda N, et al. Among authors: nishio k. Int J Clin Oncol. 2025 Dec 22. doi: 10.1007/s10147-025-02942-8. Online ahead of print. Int J Clin Oncol. 2025. PMID: 41430003
RELAY+: Final Overall Survival With Ramucirumab Plus Gefitinib in Patients With Untreated EGFR-Mutated Metastatic NSCLC.
Nishio M, Seto T, Reck M, Garon EB, Nishio K, Kasahara K, Nishino K, Satouchi M, Yoh K, Hayashi H, Sakai K, Enatsu S, Matsui T, Varughese SC, Carlsen M, Visseren-Grul C, Nakagawa K. Nishio M, et al. Among authors: nishio k. JTO Clin Res Rep. 2025 Sep 26;6(12):100912. doi: 10.1016/j.jtocrr.2025.100912. eCollection 2025 Dec. JTO Clin Res Rep. 2025. PMID: 41278399 Free PMC article.
1,256 results